Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company ...

The investment community will be closely monitoring the performance of Pfizer in its forthcoming earnings report. The company is scheduled to release its earnings on August 5, 2025.

Pfizer: Competitive Advantages Still Exist, but Signs of Erosion Lead Us to Lower Our Valuation We’ve also reduced the firm’s moat rating from wide to narrow.

Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential 29% upside. Click here to read.

Our Top 5 Analyst Questions Pfizer’s Q1 Earnings Call Vamil Divan (Guggenheim): Asked about Pfizer’s ability to maintain and grow its dividend amid tariff uncertainty and cash flow pressure.

Pfizer’s Q1 earnings call delivered a rollercoaster of cautious optimism. CEO Albert Bourla credited solid execution in oncology and internal medicine for cushioning the COVID product sales slump. CFO ...

Pfizer’s 7%+ yield is tempting, but rising political, regulatory, and business risks threaten its stability and growth outlook. Read why PFE stock is a Hold.